Current status of angiotensin receptor blockers for the treatment of cardiovascular diseases: focus on telmisartan

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of Human Hypertension

• Publication date

  2005-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/sj.jhh.1001808PMID 15660122
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Telmisartan

  2012cited by this paper
• A Review on Telmisartan: A Novel, Long-Acting Angiotensin II-Receptor Antagonist

  2006cited by this paper
• Circadian variation of plaque rupture in acute myocardial infarction.

  2004cited by this paper
• Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study.

  2004cited by this paper
• Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks.

  2003cited by this paper
• Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

  2003cited by this paper
• What did we learn from the OPTIMAAL trial? What can we expect from VALIANT?

  2003cited by this paper
• The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

  2003cited by this paper
• Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.

  2003cited by this paper
• Evaluation of Angiotensin II Receptor Blockers for 24‐Hour Blood Pressure Control: Meta‐Analysis of a Clinical Database

  2003cited by this paper
• Long-Term Effects of Irbesartan and Atenolol on the Renin-Angiotensin-Aldosterone System in Human Primary Hypertension: The Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA)

  2003cited by this paper
• Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack.

  2003cited by this paper
• Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.

  2003cited by this paper
• Albuminuria and Cardiovascular Risk in Hypertensive Patients with Left Ventricular Hypertrophy: The LIFE Study

  2003cited by this paper
• Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

  2003cited by this paper
• A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly.

  2003cited by this paper
• Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study.

  2002cited by this paper
• Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study

  2002cited by this paper
• Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan.

  2002cited by this paper
• Microalbuminuria Reduction With Valsartan in Patients With Type 2 Diabetes Mellitus: A Blood Pressure–Independent Effect

  2002cited by this paper
• Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

  2002cited by this paper
• Comparison of trough effect of telmisartan vs perindopril using self blood pressure measurement: EVERESTE study

  2002cited by this paper
• Comparison of a Fixed-Dose Combination of 40 mg Telmisartan Plus 12.5 mg Hydrochlorothiazide With 40 mg Telmisartan in the Control of Mild to Moderate Hypertension

  2002cited by this paper
• From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis.

  2002cited by this paper
• ACE Inhibitors and Protection Against Kidney Disease Progression in Patients With Type 2 Diabetes: What's the Evidence?

  2002cited by this paper
• Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.

  2002cited by this paper
• Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

  2002cited by this paper
• Diabetic nephropathy: can renoprotection be extrapolated to cardiovascular protection?

  2002cited by this paper
• Angiotensin receptor blockers: how important is selectivity?

  2002cited by this paper
• Endothelial Cell Dysfunction Leading to Diabetic Nephropathy: Focus on Nitric Oxide

  2001cited by this paper
• Efficacy and tolerability of a fixed-dose combination of telmisartan plus hydrochlorothiazide in patients uncontrolled with telmisartan monotherapy

  2001cited by this paper
• Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial.

  2001cited by this paper
• Cardiovascular risk and therapeutic intervention for the early morning surge in blood pressure and heart rate

  2001cited by this paper
• Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

  2001cited by this paper
• Effects of the replacement of the angiotensin converting enzyme inhibitor enalapril by the angiotensin II receptor blocker telmisartan in patients with congestive heart failure. The replacement of angiotensin converting enzyme inhibition (REPLACE) investigators.

  2001cited by this paper
• Cyclic and circadian variations in cardiovascular events.

  2001cited by this paper
• ACE inhibitors in heart failure: are they irreplaceable?

  2001cited by this paper
• Combination treatment with telmisartan and hydrochlorothiazide in black patients with mild to moderate hypertension

  2001cited by this paper
• Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study.

  2001cited by this paper
• Comparative Efficacy of Olmesartan, Losartan, Valsartan, and Irbesartan in the Control of Essential Hypertension

  2001cited by this paper
• Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack.

  2001cited by this paper
• Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

  2001cited by this paper
• Circadian rhythms and clinical medicine with applications to hypertension.

  2001cited by this paper
• A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.

  2001cited by this paper
• Pharmacology of AT 1 -receptor Blockers

  2001cited by this paper
• Renoprotection by angiotensin-receptor blockers and ACE inhibitors in hypertension.

  2001cited by this paper
• Comparison of 26-week efficacy and tolerability of telmisartan and atenolol, in combination with hydrochlorothiazide as required, in the treatment of mild to moderate hypertension: a randomized, multicenter study.

  2001cited by this paper
• Comparative Effects of Telmisartan in the Treatment of Hypertension

  2000cited by this paper
• Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

  2000cited by this paper
• Angiotensin II receptor blockers: equal or preferred substitutes for ACE inhibitors?

  2000cited by this paper
• Rationale and design of diabetics exposed to telmisartan and enalapril (DETAIL) study.

  2000cited by this paper
• Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.

  2000cited by this paper
• Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.

  2000cited by this paper
• Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

  2000cited by this paper
• The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure

  2000cited by this paper
• Effects of eprosartan versus enalapril in hypertensive patients on the renin-angiotensin-aldosterone system and safety parameters: results from a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group.

  1999cited by this paper
• ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension

  1999cited by this paper
• Increased chymase-dependent angiotensin II formation in human atherosclerotic aorta.

  1999cited by this paper
• Elevated systolic blood pressure and risk of cardiovascular and renal disease: overview of evidence from observational epidemiologic studies and randomized controlled trials.

  1999cited by this paper
• Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension.

  1999cited by this paper
• Chymase-dependent angiotensin II formation in human vascular tissue.

  1999cited by this paper
• The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

  1999cited by this paper
• Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension.

  1998cited by this paper
• Vascular remodeling: the role of angiotensin-converting enzyme inhibitors.

  1998cited by this paper
• Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension

  1998cited by this paper
• AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism.

  1998cited by this paper
• Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system.

  1998cited by this paper
• A comparison of the efficacies and duration of action of the angiotensin II receptor blockers telmisartan and amlodipine.

  1998cited by this paper
• Candesartan cilexetil and enalapril are of equivalent efficacy in patients with mild to moderate hypertension.

  1997cited by this paper
• The subtype 2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats.

  1997cited by this paper
• Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension. Irbesartan Multicenter Investigators.

  1997cited by this paper
• Effects and Tolerability of Irbesartan Versus Enalapril in Patients With Severe Hypertension fn1

  1997cited by this paper
• Effect of Angiotensin-Converting Enzyme Inhibitors on the Progression of Nondiabetic Renal Disease

  1997cited by this paper
• Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group.

  1997cited by this paper
• Hypertension awareness, treatment and control in the community: is the ‘rule of halves’ still valid?

  1997cited by this paper
• The subtype-2 (AT2) angiotensin receptor regulates renal cyclic guanosine 3', 5'-monophosphate and AT1 receptor-mediated prostaglandin E2 production in conscious rats.

  1996cited by this paper
• Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group.

  1996cited by this paper
• Blood pressure and end-stage renal disease in men.

  1996cited by this paper
• Blood pressure as a cardiovascular risk factor: prevention and treatment.

  1996cited by this paper
• Effect of the Angiotensin-Converting–Enzyme Inhibitor Benazepril on the Progression of Chronic Renal Insufficiency

  1996cited by this paper
• Regression of media-to-lumen ratio of human subcutaneous arteries and left ventricular hypertrophy during treatment with an angiotensin-converting enzyme inhibitor-based regimen in hypertensive patients.

  1995cited by this paper
• Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials.

  1995cited by this paper
• Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension.

  1995cited by this paper
• Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension

  1995cited by this paper
• Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure

  1995cited by this paper
• Efficacy and tolerability of losartan versus enalapril alone or in combination with hydrochlorothiazide in patients with essential hypertension.

  1995cited by this paper
• Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection.

  1994cited by this paper
• The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.

  1993cited by this paper
• Heterogeneity of angiotensin synthetic pathways and receptor subtypes: physiological and pharmacological implications.

  1993cited by this paper
• Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.

  1992cited by this paper
• Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension.

  1991cited by this paper
• Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.

  1991cited by this paper
• Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias.

  1990cited by this paper
• Racial Differences in Pressure, Volume and Renin Interrelationships in Essential Hypertension

  1979cited by this paper
• Role of the Renin-Angiotensin System in the Systemic Vasoconstriction of Chronic Congestive Heart Failure

  1978cited by this paper
• Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease.

  1972cited by this paper
• PREVENTION AND TREATMENT

  1944cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• The Efficiency of Telmisartan in Hypertension Management as a Monotherapy or Combined; Literature Review

  2021influential citation
• Effect of Reaction Parameters on the Lipase-Catalyzed Kinetic Resolution of (RS )-Metoprolol

  2020cites this paper
• Low body mass index is a risk factor for hyperkalaemia associated with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers treatments

  2018cites this paper
• Effect of hydrochlorothiazide in addition to telmisartan/amlodipine combination for treating hypertensive patients uncontrolled with telmisartan/amlodipine: a randomized, double-blind study

  2016cites this paper
• Telmisartan exerts sustained blood pressure control and reduces blood pressure variability in metabolic syndrome by inhibiting sympathetic activity.

  2014cites this paper
• Comparative efficacy and safety of triple therapy (ramipril, telmisartan, hydrochlorothiazide) vs dual anti hypertensive therapy (ramipril or telmisartan, hydrochlorothiazide) in stage 2 hypertensive patients.

  2014cites this paper
• Educational Forum Azilsartan medoxomil: Angiotensin receptor blocker in the treatment of hypertension

  2013cites this paper
• Antihypertensive and metabolic effects of high-dose olmesartan and telmisartan in type 2 diabetes patients with hypertension.

  2013cites this paper
• Current status of β-blockers for the treatment of hypertension: an update.

  2012cites this paper
• Telmisartan - An effective antihypertensive for 24-hour blood pressure control

  2012cites this paper
• Telmisartan

  2012cites this paper
• Telmisartan Improves Morphologic and Functional Changes in Both Left Ventricular Myocardium and Carotid Arterial Wall in Patients with Hypertension: Assessment by Tissue Doppler Imaging and Carotid Ultrasonography

  2010cites this paper
• The Role of Angiotensin Receptor Blocker and Calcium Channel Blocker Combination Therapy in Treating Hypertension

  2010cites this paper
• Beneficial effects of telmisartan on left ventricular structure and function in patients with hypertension determined by two-dimensional strain imaging

  2009cites this paper
• The treatment of hypertension with telmisartan in the sphere of circadian rhythm in metabolic syndrome in the elderly.

  2009cites this paper
• Angiotensin 11 receptor antagonists (ATI blockers, ARBs, sartans): similarities and differences

  2008cites this paper
• Comparison of the Effects of Telmisartan and Olmesartan on Home Blood Pressure, Glucose, and Lipid Profiles in Patients with Hypertension, Chronic Heart Failure, and Metabolic Syndrome

  2008cites this paper
• Current and Future Status of Beta‐blockers in the Treatment of Hypertension

  2008cites this paper
• [Antihypertensive and metabolic effects of telmisartan in patients with the metabolic syndrome in primary care--a field study].

  2007cites this paper
• Antihypertensive und metabolische Effekte von Telmisartan bei Patienten mit metabolischem Syndrom in der Praxis – eine Anwendungsbeobachtung

  2007cites this paper
• Pharmacoeconomics and quality of life analysis of telmisartan in hypertension treatment

  2007cites this paper
• Beta-Blockers as First Line Treatment of Hypertension: A Proponents View

  2007cites this paper
• Use of 24-h ambulatory blood pressure monitoring to assess blood pressure control: a comparison of olmesartan medoxomil and amlodipine besylate

  2006cites this paper
• Clinical experience with the use of angiotensin receptor blockers in patients with cardiovascular, cerebrovascular and renal diseases.

  2006cites this paper
• The Pleiotropic Effects of Angiotensin Receptor Blockers

  2006cites this paper
• Beneficial Effect of Cilnidipine on Morning Hypertension and White-Coat Effect in Patients with Essential Hypertension

  2006cites this paper